KHB(SZ:002022) Sou Hu Cai Jing·2025-06-09 08:38Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kehua Bio-engineering Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1] - As of the first quarter of 2025, Kehua Bio has a total market capitalization of 3.199 billion yuan and a price-to-book ratio of 0.98, which is the lowest in 21 days [1] - The company reported a revenue of 388 million yuan for the first quarter of 2025, representing a year-on-year decrease of 12.50%, and a net loss of approximately 53.26 million yuan, a decline of 84.79% year-on-year [1] Group 2 - Kehua Bio's main business includes the research, production, and sales of in vitro diagnostic reagents and medical testing instruments, with key products in biochemical diagnosis, immunodiagnosis, and molecular diagnosis [1] - The company has received several honors, including the National Science and Technology Progress Award and recognition as a National High-tech Enterprise [1] - In comparison to industry averages, Kehua Bio's price-to-earnings ratio (TTM) is -4.81, while the industry average is 50.64, indicating a significant underperformance relative to peers [2]